Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of H2 Haplotype and CYP3A5 on Clopidogrel Response in PCI
NCT00433784Phase 4Completed
- Start
- Sep 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of clopidogrel in coronary artery disease (CAD). Primary endpoint: Inhibitory effect of clopidogrel on platelet aggregation. Started Sep 2004; status: completed.
02
Drugs
clopidogrel
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT00433784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00433784.